Oxidant stress as a major determinant of platelet activation in invasive breast cancer

The hypothesis that increased oxidative stress in breast cancer (BC) patients could induce enhanced lipid peroxidation, which, in turn, would contribute to platelet activation and poor clinical outcome is attractive. To address this issue, we investigated pre-surgical urinary 8-iso-prostaglandin (PG)F-2 (marker of in vivo oxidative stress) and 11-dehydro-thromboxane (TX)B-2 (marker of in vivo platelet activation) levels in patients with primary BC (n=115) compared with control women paired for comorbidities and their association with patients' metabolic profile and clinical prognostic factors. The results obtained showed that presurgical urinary excretion of both biomarkers was enhanced in BC patients compared to controls and was associated with patients' estrogen receptor (ER) expression, but not HER2 status or Ki67 proliferation index. Accordingly, both urinary biomarkers were increased in patients with luminal-like BC molecular subtypes compared with triple negative or HER2-enriched tumors. ER status was an independent predictor of 8-iso-PGF(2) urinary levels, which, in turn, significantly predicted 11-dehydro-TXB2 urinary levels together with disease stage and ER status. The prognostic value of 11-dehydro-TXB2 was then evaluated showing a significant correlation with BC pathological response to neoadjuvant treatment. Furthermore, among relapsing patients, those with elevated urinary biomarker levels were more likely to develop distant metastasis rather than local recurrence. In conclusion, we may speculate that enhanced oxidative stress due to estrogen-related mechanisms might cause a condition of persistent platelet activation capable of sustaining BC growth and progression through the release of bioactive stored molecules, ultimately contributing to tumor invasiveness. Further studies specifically addressing this hypothesis are presently needed. What's new? The hypothesis that increased oxidative stress in breast cancer (BC) patients could induce enhanced lipid peroxidation, which, in turn, would contribute to platelet activation and poor clinical outcome is attractive. Here, the authors found that enhanced oxidative stress due to estrogen-related mechanisms might cause a condition of platelet activation (as evidenced by enhanced 11-dehydro-thromboxane B-2 urinary excretion levels) capable of sustaining BC growth and progression, ultimately contributing to tumor invasiveness. Determination of 11-dehydro-thromboxane B-2 urinary excretion prior to treatment might improve risk stratification in selected categories of patients, i.e., those with locally advanced luminal-like BC molecular types undergoing neoadjuvant treatment.